Accretion Pha.

- The company has recently completed a successful IPO in May 2025, raising INR29.75 crores. - Proceeds from the IPO have been strategically utilized for manufacturing facility upgrades, debt repayment, and working capital augmentation. - Short-term and long-term borrowings have drastically reduced due to loan repayments post-IPO. - There is no mention of any immediate or planned new fundraising through debt or equity in the call. - The company emphasizes maintaining a healthy capital structure with low debt-to-equity ratio and adequate liquidity for future expansion. - Focus remains on profitable growth, working capital efficiency, and prudent capital management without indicating any additional fundraising efforts currently.

- The company has undertaken a capex resulting in approximately a 40% increase in production capacity, funded in part by proceeds from its IPO. - The capex includes upgrading manufacturing facilities with new equipment to enhance capacity and compliance. - Future capex plans involve continued expansion and equipment upgradation to strengthen CDMO capabilities. - Focus on expanding product registrations and regulatory approvals in markets like Rwanda, Nigeria, Cambodia, and others to support growth. - Working capital has been augmented to support growing orders and ensure operational agility. - The company aims to sustain double-digit growth with a balanced mix of domestic and export revenues backed by these investments. - Loan repayments have reduced debt, maintaining a healthy capital structure with adequate liquidity for future expansions.

- The company expects to maintain the same strong growth momentum seen in the recent quarters, targeting sustained double-digit growth in sales and revenue. - Management indicated optimism for continued rapid sales growth in upcoming years, supported by a healthy order book and expanding export markets. - They anticipate leveraging newly added production capacity (with around a 40% capacity increase post-IPO), along with improved utilization and product mix, to drive volume growth. - FY '26 revenue is expected to surpass last year's INR57 crores significantly, aiming around INR120-130 crores based on current momentum. - The company plans to expand product registrations in new geographies (e.g., Rwanda, Nigeria, Cambodia) to bolster sales channels. - Growth is supported by strategic bulk sourcing, supply diversification, efficiency gains, and tighter working capital management. - While exact figures are not confirmed, management is confident in sustaining or improving existing growth rates going forward.

- Accretion Pharmaceuticals expects to maintain the strong revenue growth momentum from H1 FY '26 into the upcoming quarters and future years, aiming for double-digit growth. - The company anticipates EBITDA margins to improve from the current ~17% toward a steady-state of 20%-22%, as registration and scaling expenses normalize. - Profit after tax (PAT) is projected to grow significantly; with confidence expressed in maintaining or exceeding current profit levels (e.g., PAT closer to INR 10 crores anticipated). - Improved capacity utilization and expanded product registrations in multiple countries (e.g., Rwanda, Nigeria, Cambodia) will drive revenue and margin expansion. - Operational efficiencies, bulk sourcing, supply diversification, and tighter working capital management are expected to enhance profitability. - Long-term focus is on sustainable, profitable growth, value creation, and increasing return ratios supported by a healthy order book and strengthened balance sheet.

- The company currently has a good order book, which supports their confidence in maintaining momentum in upcoming quarters. - They expect to sustain the growth rate seen in the first half of the year through efficient utilization of working capital and enhanced capacity. - New product launches and expansion into new countries also contribute to anticipated revenue growth from the order book. - The management confirms clarity on the existing order book and expects to deliver on these orders, contributing to PAT projections close to INR 10 crores for the year. - Although specific numbers are not disclosed, the company expresses confidence based on established products and customer relationships.